Business Wire

EcoOnline Celebrates Longstanding Partnership with Menzies Aviation, Driving Safety Culture Across the Globe

16.1.2025 09:00:00 CET | Business Wire | Press release

Share

EcoOnline is proud to celebrate the continued success of its partnership with Menzies Aviation, the leading service partner to the world’s airports and airlines. Since 2019, EcoOnline has played a key role in enhancing the company’s MORSE (Menzies Operating Responsibly, Safely and Efficiently) system, driving safety culture and compliance across the company’s global network.

With a presence at more than 295 airports in over 65 countries, Menzies Aviation operates in high-risk environments, where safety is embedded in its DNA. As Malcolm Rae, Head of Risk Systems & Data at Menzies, reflects, “We influence safety from the moment passengers walk into an airport to when they leave. We live and breathe it day in, day out—not just in the risk and safety team, but every employee takes it extremely seriously.”

Technology That Drives Safety at Every Level

The longstanding collaboration with EcoOnline has enabled Menzies Aviation to implement a more efficient, data-driven approach to incident reporting, risk management and compliance tracking. Using EcoOnline’s advanced EHS (environment, health, and safety) solution—the technology behind Menzies’ MORSE reporting system—employees are empowered to quickly identify risks, make informed decisions, and proactively address safety risks in real time.

Since adopting EcoOnline’s platform in 2019, Menzies has seen remarkable improvements:

  • 128% increase in employee hazard reporting.
  • Serious personal injury reduced from 1.8 per 1,000 full-time employees in 2019 to 0.94 in 2022 and 0.7 in 2023.

"If you want to be an industry leader, you've got to know where your risks are, and that starts with empowering every employee to act. EcoOnline’s EHS platform equips everyone with the tools to report hazards and ensure our people go home safely," said Graham Cowing, Vice President of Safety Standards, Menzies Aviation.

Board Commitment to Safety

Safety at Menzies is championed at every level, from frontline workers to the boardroom. Graham commented:"Safety is a core value that starts with leadership. Every executive member is committed to getting involved, and initiatives like ‘Take 10 for Safety,’ where every board meeting begins with a safety-focused discussion, are supported by real-time dashboards from EcoOnline. These insights keep safety central to decision-making and drive accountability across the organisation."

MORSE: A system, culture and celebration

Menzies’ approach to safety is defined by its MORSE cultural mindset, MORSE safety systems, and immersive bi-annual MORSE Week events. Its most recent MORSE Week, which took place from 28 October – 1 November 2024 focused on emergency response planning, offering tools, support, and guidance to help its global teams reaffirm their commitment to safety through learning and team-building opportunities.

Tom Goodmanson, CEO of EcoOnline, commented, "By prioritising safety and collaboration, Menzies Aviation—together with EcoOnline—is setting new benchmarks for industry standards, ensuring a safer, more secure environment for employees and customers. It’s impressive that Graham still says, ‘more work is to be done,’ as it reflects Menzies’ commitment to continuous improvement."

Learn from Menzies’ safety success—explore the full case study here.

Visit ecoonline.com to immediately and positively impact your workplace safety and sustainability.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250116891021/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye